SOX8 and colorectal carcinoma: Similar observations were found in CRC where SOX8 was shown to be involved in promoting resistance to cetuximab, an epidermal growth factor receptor inhibitor used for treatment against metastatic CRC, head, and neck cancer (Piao et al., 2022; Sun et al., 2020).